Safety and Efficacy of Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19 Population.
Yasar SattarPradeeksha MukuntharajMohamed ZghouziAbdul-Rahman M SuleimanHassan AttiqueWaqas UllahMuhammad Khawar SanaNathan ZaherMaham MehmoodRajkumar P DoshiAnkur PanchalTanveer MirMuhammad NadeemOmar E AliMohamad MohamedRodrigo BagurIslam Y ElgendyMamas A MamasMohamed Chadi AlraiesPublished in: High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension (2021)
COVID-19 is not a contraindication to hold or discontinue RAASi as they are not associated with higher mortality or worsening symptoms. Continuation of RAASi might be associated with favorable outcomes in COVID-19, including seropositivity/viral clearance.